| Nov 13 |
MSD and AstraZeneca report positive topline data from Koselugo trial for NF1
|
| Nov 12 |
Merck, AstraZeneca report positive data for Koselugo in adults
|
| Nov 12 |
With 79% ownership, Merck & Co., Inc. (NYSE:MRK) boasts of strong institutional backing
|
| Nov 12 |
KOSELUGO® (selumetinib) Showed Significant and Clinically Meaningful Improvement in Objective Response Rate Versus Placebo in Adults With Neurofibromatosis Type 1 who Have Symptomatic, Inoperable Plexiform Neurofibromas in Global Phase 3 KOMET Trial
|
| Nov 12 |
Merck to Present New Data From GARDASIL®9 Studies Reinforcing the Importance of Gender-Neutral HPV Vaccination in Adults Up to Age 45 at the International Papillomavirus Conference (IPVC) 2024
|
| Nov 11 |
Citius Pharmaceuticals reports positive early stage results of cancer combo treatment
|
| Nov 9 |
Merck & Co., Inc. (MRK): Among the Best Low Volatility Stocks to Invest In Now
|
| Nov 8 |
Canada's Drug Agency Recommends WINREVAIR® (sotatercept) for Reimbursement
|
| Nov 8 |
Why WEC Energy, Merck And Regions Financial Are Winners For Passive Income
|
| Nov 8 |
Stocks to watch next week: Burberry, SSE, Disney, Alibaba and AstraZeneca
|
